| Entry |
|
|---|
| Name |
Clofarabine (JAN/USAN/INN);
Clolar (TN) |
|---|
| Product |
|
|---|
| Generic |
CLOFARABINE (Amneal Pharmaceuticals LLC), CLOFARABINE (Apotex Corp.), CLOFARABINE (Cadila Healthcare Limited), CLOFARABINE (Dr.Reddy's Laboratories), CLOFARABINE (Fosun Pharma USA), CLOFARABINE (Fresenius Kabi USA), CLOFARABINE (Gland Pharma Limited), CLOFARABINE (Ingenus Pharmaceuticals), CLOFARABINE (Meitheal Pharmaceuticals), CLOFARABINE (Mylan Institutional LLC), CLOFARABINE (Winthrop U.S.) |
|---|
| Formula |
C10H11ClFN5O3
|
|---|
| Exact mass |
303.0534
|
|---|
| Mol weight |
303.6774
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Antineoplastic
DG02018 Antimetabolite, antineoplastic
DG01958 Nucleic acid derivative, antineoplastic
DG01439 Arabinofuranosyl type antineoplastic
|
|---|
| Remark |
| Therapeutic category: | 4229 |
|
|---|
| Efficacy |
Antineoplastic, Antimetabolite |
|---|
| Disease |
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01B ANTIMETABOLITES
L01BB Purine analogues
L01BB06 Clofarabine
D03546 Clofarabine (JAN/USAN/INN) <JP/US>
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
422 Antimetabolites
4229 Others
D03546 Clofarabine (JAN/USAN/INN)
Target-based classification of drugs [BR:br08310]
Enzymes
Oxidoreductases (EC1)
Ribonucleoside-diphosphate reductase
RRM1
D03546 Clofarabine (JAN/USAN/INN) <JP/US>
Transferases (EC2)
DNA polymerase
POLA
D03546 Clofarabine (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D03546
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D03546
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D03546
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D03546
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 20
1 C1y C 23.0884 -19.5314
2 C1y C 24.4740 -19.5314
3 C1y C 24.9021 -18.2136
4 O2x O 23.7812 -17.3992
5 C1y C 22.6603 -18.2136
6 N5x N 27.3020 -19.5991
7 C8y C 27.3020 -18.2136
8 N4y N 26.1021 -17.5208
9 C1b C 21.4603 -17.5208
10 O1a O 20.2604 -18.2136
11 X F 25.2884 -20.6523
12 O1a O 22.2740 -20.6523
13 C8y C 28.5019 -20.2919
14 N5x N 29.7019 -19.5991
15 C8y C 29.7019 -18.2136
16 C8y C 28.5019 -17.5208
17 C8x C 26.5178 -16.1371
18 N5x N 28.0862 -16.1367
19 X Cl 28.5019 -21.6790
20 N1a N 30.9035 -17.5196
BOND 22
1 1 2 1
2 2 3 1
3 3 4 1
4 4 5 1
5 1 5 1
6 6 7 1
7 7 8 1
8 3 8 1 #Up
9 5 9 1 #Up
10 9 10 1
11 2 11 1 #Up
12 1 12 1 #Down
13 6 13 2
14 13 14 1
15 14 15 2
16 15 16 1
17 7 16 2
18 8 17 1
19 16 18 1
20 17 18 2
21 13 19 1
22 15 20 1
|
|---|
